Phase 2 Parkinson's Disease Trial, Recruiting NCT06629389 Sponsor: Laboratorio Elea Phoenix S.A. Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 2 Parkinson's Disease Trial, Recruiting

NCT06629389
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 40 and 80 years old.
  • You have been diagnosed with Parkinson's disease (PD) that is considered mild to moderate in severity.
  • Your Parkinson's medications and doses have not changed in the last month before joining the study.
  • You are able to understand the study and willing to sign a consent form agreeing to take part.

Who may not be able to join:

  • You have been diagnosed with dementia or scored below 24 on a standard memory and thinking test.
  • You have a serious psychiatric condition, such as severe depression or psychosis that has not responded to treatment, or you have ever been admitted to a psychiatric or mental health facility (regardless of when or why).
  • You have a known or suspected allergy to cannabinoids (cannabis-related substances) or any inactive ingredients in the study medication.
  • You have a history of drug or alcohol dependence.
  • You have taken dopamine-blocking medications within the last 180 days before joining the study.
  • You have used amphetamines, cocaine, or certain antidepressants called MAO-A inhibitors within the last 90 days.
  • You have taken certain specific medications — including valproic acid, felbamate, high-dose niacin, high-dose nicotinamide, isoniazid, ketoconazole, or clobazam — within the last 90 days (confirm with trial site).
  • Your blood test results show certain abnormal levels that suggest an unstable medical condition (confirm specific values with trial site).
  • You have moderate to severe liver disease.
  • You are currently pregnant or breastfeeding.
  • You are a woman of childbearing age and are not willing to use at least one reliable form of contraception during the study and for at least four weeks after finishing treatment.
  • You have previously had surgery for Parkinson's disease, such as deep brain stimulation or a procedure to create a lesion in the brain.
  • You were diagnosed with Parkinson's disease less than 5 years ago.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Marina Sanchez Abraham, Neurologa, Hospital Español de Mendoza

Phone: 1144898300

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Laboratorio Elea Phoenix S.A.
Registry
ClinicalTrials.gov
Start date
28 November 2024
Est. completion
1 November 2025

Where this trial is recruiting

🇦🇷 Argentina

Primary endpoints

Number of patients with advers events related to treatment acording to CTCAE v5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov